Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

January 27, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside

January 13, 2025

Via AB Newswire

Topics Regulatory Compliance

Where Sage Therapeutics Stands With Analysts ↗

January 02, 2025

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

December 16, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics ↗

November 20, 2024

Via Benzinga

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In ↗

January 13, 2025

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Via Stocktwits

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗

January 13, 2025

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.

Via Benzinga

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗

January 13, 2025

Via Benzinga

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗

January 13, 2025

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

Via Benzinga

Sage Therapeutics's Earnings: A Preview ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

From Sage Therapeutics

Via Business Wire

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

January 10, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

January 08, 2025

From Sage Therapeutics

Via Business Wire

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

From Sage Therapeutics, Inc.

Via Business Wire

This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 21, 2024

Via Benzinga

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder ↗

November 20, 2024

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.

Via Benzinga

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

November 20, 2024

From Sage Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

October 29, 2024

From Sage Therapeutics, Inc.

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)

October 25, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

October 23, 2024

From Rosen Law Firm

Via Business Wire

Faruqi & Faruqi Reminds Sage Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE

October 23, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

October 22, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline

October 21, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗

October 17, 2024

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and...

Via Benzinga

Topics Workforce

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio

October 17, 2024

From Sage Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.